» Articles » PMID: 26438065

P-cadherin and the Journey to Cancer Metastasis

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2015 Oct 7
PMID 26438065
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

P-cadherin is a classical cell-to-cell adhesion molecule with a homeostatic function in several normal tissues. However, its behaviour in the malignant setting is notably dependent on the cellular context. In some tumour models, such as melanoma and oral squamous cell carcinoma, P-cadherin acts as a tumour suppressor, since its absence is associated with a more aggressive cancer cell phenotype; nevertheless, the overexpression of this molecule is linked to significant tumour promoting effects in the breast, ovarian, prostate, endometrial, skin, gastric, pancreas and colon neoplasms. Herein, we review the role of P-cadherin in cancer cell invasion, as well as in loco-regional and distant metastatic dissemination. We focus in P-cadherin signalling pathways that are activated to induce invasion and metastasis, as well as cancer stem cell properties. The signalling network downstream of P-cadherin is notably dependent on the cellular and tissue context and includes the activation of integrin molecules, receptor tyrosine kinases, small molecule GTPases, EMT transcription factors, and crosstalk with other cadherin family members. As new oncogenic molecular pathways mediated by P-cadherin are uncovered, putative therapeutic options can be tested, which will allow for the targeting of invasion or metastatic disease, depending on the tumour model.

Citing Articles

Role of E-cadherin in epithelial barrier dysfunction: implications for bacterial infection, inflammation, and disease pathogenesis.

Lialios P, Alimperti S Front Cell Infect Microbiol. 2025; 15:1506636.

PMID: 40007608 PMC: 11850337. DOI: 10.3389/fcimb.2025.1506636.


Outside-in engineering of cadherin endocytosis using a conformation strengthening antibody.

Xie B, Xu S, Sivasankar S Nat Commun. 2025; 16(1):1157.

PMID: 39881179 PMC: 11779849. DOI: 10.1038/s41467-025-56478-6.


A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.

Mahalingam D, Owonikoko T, Delpassand E, Mulcahy M, Kalyan A, Ulahannan S Cancer. 2025; 131(1):e35680.

PMID: 39748726 PMC: 11696210. DOI: 10.1002/cncr.35680.


Serum Level of Cadherin-P (CDH3) Is a Novel Predictor of Cardiovascular Events Related to Atherosclerosis in a 3-Year Follow-Up Study.

Gumanova N, Vasilyev D, Bogdanova N, Drapkina O J Clin Med. 2024; 13(21).

PMID: 39518432 PMC: 11546736. DOI: 10.3390/jcm13216293.


Hsa_circ_0023179 modulated the processes of proliferation, apoptosis, and EMT in non-small cell lung cancer cells via the miR-615-5p/CDH3 axis.

Guo Q, Zheng M, Zhu C, Wu B Biomol Biomed. 2024; 25(1):155-164.

PMID: 39159001 PMC: 11647264. DOI: 10.17305/bb.2024.10944.


References
1.
Hulpiau P, van Roy F . Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2008; 41(2):349-69. DOI: 10.1016/j.biocel.2008.09.027. View

2.
Van Marck V, Stove C, Jacobs K, Van den Eynden G, Bracke M . P-cadherin in adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer. 2010; 128(5):1031-44. DOI: 10.1002/ijc.25427. View

3.
Indelman M, Leibu R, Jammal A, Bergman R, Sprecher E . Molecular basis of hypotrichosis with juvenile macular dystrophy in two siblings. Br J Dermatol. 2005; 153(3):635-8. DOI: 10.1111/j.1365-2133.2005.06734.x. View

4.
Radice G, Robinson S, Rayburn H, Chodosh L, Takeichi M, Hynes R . Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol. 1997; 139(4):1025-32. PMC: 2139972. DOI: 10.1083/jcb.139.4.1025. View

5.
Bagutti C, Speight P, Watt F . Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol. 1999; 186(1):8-16. DOI: 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H. View